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Essential for detection of relevant external stimuli and for fear processing, the amygdala is under modulatory inﬂuence of
dopamine (DA). The DA transporter (DAT) is of fundamental importance for the regulation of DA transmission by mediating
reuptake inactivation of extracellular DA. This study examined if a common functional variable number tandem repeat
polymorphism in the 3′ untranslated region of the DAT gene (SLC6A3) inﬂuences amygdala function during the processing of
aversive emotional stimuli. Amygdala reactivity was examined by comparing regional cerebral blood ﬂow, measured with positron
emission tomography and [
15O]water, during exposure to angry and neutral faces, respectively, in a Swedish sample comprising 32
patients with social anxiety disorder and 17 healthy volunteers. In a separate US sample, comprising 85 healthy volunteers studied
with blood oxygen level-dependent functional magnetic resonance imaging, amygdala reactivity was assessed by comparing the
activity during exposure to threatening faces and neutral geometric shapes, respectively. In both the Swedish and the US sample, 9-
repeat carriers displayed higher amygdala reactivity than 10-repeat homozygotes. The results suggest that this polymorphism
contributes to individual variability in amygdala reactivity.
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INTRODUCTION
Brain imaging studies demonstrate that the human amygdala is
activated by external fear-inducing stimuli
1–3 and that its reactivity
is the subject of considerable interindividual variation. An
inﬂuence of dopamine (DA) on amygdala function is well
established on the basis of animal experiments,
4–6 and gains
support by recent functional neuroimaging studies in humans.
The amygdala activation observed in healthy individuals during
processing of angry and fearful faces is thus enhanced by the DA
releaser amphetamine
7 and reduced in patients with Parkinson’s
disease, but partially restored after DA repletion in the latter
group.
8 In line with these ﬁndings, acute treatment with DA D2
receptor antagonists resulted in a considerable attenuation of
amygdala reactivity.
9 Moreover, DA storage in the human
amygdala, measured with 6-[
18F]ﬂuoro-L-DOPA positron emission
tomography (PET), correlates with changes in amygdala blood
oxygen levels during presentation of negative emotional visual
stimuli.
10
The DA transporter (DAT) mediates the active reuptake of
extracellular DA into presynaptic terminals after release, and is
hence a fundamental regulator of dopaminergic neurotransmis-
sion, determining the duration and amplitude of DA action. In
addition, it is the molecular target for central stimulants such as
amphetamine, which act by reversing the direction of transmitter
transport.
11 A variable number of tandem repeats (VNTR)
polymorphism in the DAT gene (SLC6A3)3 ′ untranslated region
comprises 3–11 repeats of 40bp each, with the 9- and 10-repeat
variants being the most common in Caucasians.
12 The results of
studies exploring the inﬂuence of this polymorphism on DAT
expression have not been unanimous, but the weight of evidence
suggests the 9-repeat allele to be associated with higher DAT
expression and hence with higher DA reuptake.
13–23
In the present study, we have explored the possible inﬂuence of
SLC6A3 3′ untranslated region VNTR genotype on amygdala
reactivity by using previously collected information regarding
regional cerebral blood ﬂow (rCBF) measured with PET during
presentation of angry and neutral faces, respectively, in one
Swedish sample comprising 32 subjects with social anxiety
disorder (SAD) and 17 healthy volunteers. Subsequently, in an
attempt to shed further light on the association between
genotype and amygdala reactivity found in the Swedish sample,
the possible association between SLC6A3 genotype and amygdala
reactivity was assessed with another facial stimuli test using blood
oxygen level-dependent (BOLD) functional magnetic resonance
imaging (fMRI) in a cohort comprising 85 healthy volunteers from
the US.
MATERIALS AND METHODS
Participants
PET study. The Swedish sample comprised 32 medication-free SAD
patients (for sex and age: see Table 1; for details, see Furmark et al.
24) and
17 healthy volunteers (8 men, 9 women, mean age 35.2 years); both
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www.nature.com/tpsubgroups had been enrolled through newspaper advertisements for
studies that have been published previously.
24 Originally 34 patients and
18 healthy volunteers assessed with PET were planned to be included in
this study, but two patients and one healthy volunteer were excluded due
to genotyping failure. According to self-report, all subjects in both samples
were of Caucasian origin. Following a short telephone interview, the
patients were asked to answer a battery of SAD questionnaires, and
psychiatric status was evaluated by a clinical psychologist using face-to-
face structured diagnostic interviews.
25 A psychiatrist then conducted a
MINI interview
26 to exclude depressive disorder and other major
psychiatric conditions except for comorbid anxiety disorders. To be
included, the patients should meet DSM-IV
27 criteria for SAD and display
marked anxiety for public speaking. Major criteria for exclusion from the
study were treatment for SAD during the past six months, chronic use of
prescribed medication, substance abuse, pregnancy, menopause, left-
handedness, previous PET examinations and any major somatic condition
that could be expected to inﬂuence the outcome of the study (such as
major neurological diseases). The same exclusion criteria, as well as any
ongoing psychiatric disorder, were applied also to controls.
The Uppsala University medical faculty ethical review board and the
local radiation protection committee at Uppsala University Hospital
approved the study. The participants gave informed consent in writing
after having the procedure and its consequences explained to them.
fMRI study. After the removal of ﬁve multivariate outliers (see below), the
US sample used in the analyses comprised 85 genotyped participants (for
sex and age: see Table 1) that were recruited for the fMRI study from the
Adult Health and Behaviour project, an archival database encompassing
detailed measures of behavioral and biological traits among a community
sample of 1379 nonpatient, middle-aged volunteers. According to self-
reports, all subjects in the US sample were Caucasians. All participants
were in good general health and free of the following study exclusions:
(1) medical diagnoses of cancer, stroke, diabetes requiring insulin
treatment, chronic kidney or liver disease or a lifetime history of psychotic
symptoms; (2) use of psychotropic, glucocorticoid or cardiovascular (for
example, antihypertensive, antiarrythmic) medication; (3) conditions
affecting cerebral blood ﬂow and metabolism (for example, hypertension);
and (4) any current DSM-IV Axis I disorder as assessed by face-to-face
structured diagnostic interview. Written informed consent according to the
guidelines of the University of Pittsburgh Institutional Review Board was
provided by all participants before their participation in the neuroimaging
subcomponent of Adult Health and Behaviour.
Genotyping
PET study. Genomic DNA was extracted from plasma samples using
QIAamp DNA kit (QIAGEN, Hilden, Germany). VNTR genotyping was
achieved by amplifying part of the 3′ untranslated region with the
polymerase chain reaction on a Perkin Elmer 9700 (PerkinElmer, Foster
City, CA, USA) thermal cycler using 50ng of genomic DNA, 0.15 μM of
forward (5′-TGTGGTGTAGGGAACGGCCTGAG-3′) and reverse primer (5′-
CTTCCTGGAGGTCACGGCTCAAGG-3′), 0.2mM dNTP and 1.0U HotStarTaq
DNA polymerase (QIAGEN) in a buffered (QIAGEN HotStarTaq PCR Buffer)
solution. The cycling conditions for ampliﬁcation consisted of an initial
denaturation period of 15min at 95°C, followed by 45 cycles of 25s at 95°
C and 40s at 72°C, followed by 10min at 72°C. Analysis on a 3% agarose
gel yielded distinct bands for the 9- and 10-repeat alleles. The two SLC6A3
VNTR genotype groups did not differ with respect to age.
fMRI study. In the US sample, high molecular weight DNA was isolated
from EDTA anticoagulated whole blood samples obtained from all
participants in the fMRI study using the Puregene kit (Gentra Systems,
Minneapolis, MN, USA). Each sample was genotyped for the SLC6A3 3′
untranslated region VNTR using the protocol of Vandenbergh et al.
28 All
genotypes were scored by two independent readers by comparison with
sequence veriﬁed standards and all call rates were 495%.
Brain imaging techniques
PET study. The Swedish sample was assessed by means of PET at Uppsala
PET Centre using a 32-ring ECAT EXACT HR+ PET scanner (Siemens/CTI,
Munich, Germany) that enables acquisition of 63 contiguous planes of data
with a distance of 2.46 mm, resulting in a total axial ﬁeld of view of
155mm. Before recording, subjects were placed in the scanner, had their
heads gently ﬁxated and were inserted with a venous catheter for tracer
injections. A 10-min transmission scan using three retractable
68Ge rotating
line sources was performed. Subjects were then intravenously injected
with the [
15O] labeled water tracer (approximately 10MBqkg
−1 body
weight). The emission scan started automatically in three-dimensional
mode when the bolus reached the brain (50,000 counts per second), and
consisted of three 30-s frames. The experimental task (see below)
commenced immediately following tracer injection. Emission scans were
reconstructed with a ﬁlter back projection using an 8 mm Hanning ﬁlter,
resulting in a spatial resolution of about 5mm in the ﬁeld of view. Data
were corrected for photon attenuation, decay, scattered radiation and
random coincidences. After data reconstruction, a summation image of the
three frames was made to obtain a better statistical reference for
realignment and subsequent analyses. PET-images were realigned and
normalized to the Montreal Neurological Institute’s stereotactic template
ICBM152 using SPM2 (http://www.ﬁl.ion.ucl.ac.uk/spm). Images were
smoothed using a 12mm Gaussian kernel and scaled to give all scans
the same global value. Voxel size was 2×2×2mm.
fMRI study. The US sample was assessed by means of fMRI using a
Siemens 3 T MAGNETOM Allegra scanner developed speciﬁcally for
advanced brain imaging applications and characterized by increased T2*
sensitivity and fast gradients (slew rate=400Tm
−1 s
−1), which minimize
echo-spacing thereby reducing EPI geometric distortions and improving
image quality. BOLD functional images were acquired with a gradient echo
EPI sequence (TR/TE=2000 per 25ms, FOV=20cm, matrix=64×64) that
covered 34 interleaved axial slices (3mm slice thickness) aligned with the
AC-PC plane and encompassing the entire cerebrum and the majority of
the cerebellum. All scanning parameters were selected to optimize the
quality of the BOLD signal while maintaining a sufﬁcient number of slices
to acquire whole-brain data. Before the collection of fMRI data for each
participant, we acquired a reference EPI scan that we visually inspected for
artifacts (for example, ghosting), as well as for good signal across the entire
volume of acquisition, including the amygdala and ventral striatum. In
addition, an autoshimming procedure was conducted before the acquisi-
tion of BOLD data in each subject to minimize ﬁeld inhomogeneities. The
fMRI data from all 85 participants included in this study met these quality
standards. Whole brain image analysis was completed using SPM2. For
Table 1. SLC6A3 VNTR genotype frequencies, age and gender
SLC6A3 VNTR genotype Age
(mean±s.d.)
Sex
(men/women)
9/9 9/10 10/10
Swedish sample
SAD patients 2 (6.3%) 9 (28.1%) 21 (65.6%) 37.3±8.7 14 (43.8%)/18 (56.3%)
Healthy volunteers 0 (0%) 8 (47.1%) 9 (52.9%) 35.2±9.3 8 (47.1%)/9 (52.9%)
Total sample 2 (4.1%) 17 (34.7%) 30 (61.2%) 36.6±9.0 22 (44.9%)/27 (55.1%)
fMRI study
Healthy volunteers 10 (11.8%) 33 (38.8%) 42 (49.4%) 45.2±6.6 41 (48.2%)/44 (51.8%)
Abbreviations: fMRI, functional magnetic resonance imaging; SAD, social anxiety disorder; SLC6A3, dopamine transporter gene. For the Swedish population,
information both on the two subgroups (SAD patients and healthy volunteers) and on the total sample is provided.
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the time series to correct for head motion. Data sets were then selected for
their high quality (scan stability) as demonstrated by small (o2m m
translational and o1 degree rotational) motion correction. On the basis of
this criterion, data from all participants were included in subsequent
analyses. Realigned images were spatially normalized into a standard
Montreal Neurological Institute template stereotactic space using a 12-
parameter afﬁne model. These normalized images were then smoothed to
minimize noise and residual difference in gyral anatomy with a Gaussian
ﬁlter, set at 6 mm full-width at half-maximum. Voxel-wise signal intensities
were ratio normalized to the whole-brain global mean. The ﬁnal voxel size
in the fMRI analysis was 2×2×2mm.
Affective face processing tasks
PET study. Simultaneously with the [
15O]water tracer injection, a multi-
slide presentation of 2.5min was started. During the following emission
scan, participants were shown black and white photographs of angry and
neutral faces of different individuals taken from the set of Ekman and
Friesen.
29 Subjects were scanned twice and presented with 30 photo-
graphs of human faces (either angry or neutral) during each scan. The
order of presentation was counterbalanced among participants. The
procedure protocol was designed to be in line with those of previous PET
studies,
1 with each photograph being visible for 3s, followed by a 2-s
pause in which the computer screen was blank. To monitor the observance
of the participants, they were instructed to press a mouse button when a
new face was presented on the screen.
fMRI study. During fMRI scanning all 85 individuals in the US sample
participated in an affective face processing task that was similar, but not
identical, to that used in the PET experiments. The paradigm consisted of
four blocks of the affective face processing task interleaved with ﬁve blocks
of a sensorimotor control task. Subject performance (accuracy and reaction
time) was monitored during all scans. During the affective face processing
task, subjects viewed a trio of faces (expressing either anger or fear) and
selected one of two faces (bottom) identical to a target face (top). Each
affective face processing block consisted of six images, balanced for sex
and target affect (angry or fearful) all derived from a standard set of
pictures of facial affect.
29 During the sensorimotor control blocks, subjects
viewed a trio of simple geometric shapes (circles, vertical and horizontal
ellipses) and selected one of two shapes (bottom) identical to a target
shape (top). Each sensorimotor control block consisted of six different
shape trios. All blocks were preceded by a brief instruction (‘Match Faces’
or ‘Match Shapes’) lasting 2s. In the affective face processing blocks, each
of the six face trios was presented for 4s with a variable interstimulus
interval of 2–6s (mean=4 s) for a total block length of 48s. In the
sensorimotor control blocks, each of the six shape trios was presented for
4s with a ﬁxed interstimulus of 2 s for a total block length of 36s. Total task
time was 390s.
Statistical analysis
Grouping of genotypes. To increase statistical power, and in line with
previous studies on this polymorphism,
30–32 genotypes were dichotomized
so that subjects carrying at least one version of the relatively rare 9-repeat
(9/9 and 9/10) were compared with those who were homozygous carriers
of the 10-repeat (10/10). The genotype groups did not differ with respect
to age (Swedish sample: 37±7 vs 36±10; US sample: 45±7 vs 45±7).
PET study. Mean rCBF data were extracted from the entire left and right
amygdala, respectively, using the regions of interest based on the Talairach
Daemon option of the Wake Forest University (WFU) PickAtlas tool.
33
Global blood ﬂow was scaled to 1. Extracted rCBF data were statistically
evaluated in SPSS 18 (SPSS, Chicago, IL, USA) using repeated measures
analysis of variance with facial affect (neutral, angry) as within group factor,
genotype and diagnosis (SAD, control) as between group factors and sex
as a covariate.
fMRI study. Because of the relatively high resolution when using fMRI (as
compared with PET), the average of the cluster of activated voxels within
the amygdala as deﬁned in the Automated Anatomical Labeling atlas,
rather than from the entire amygdalae, were used when relating amygdala
activity to genotype in the fMRI study. To this end, following preproces-
sing, linear contrasts employing canonical hemodynamic response
functions were used to estimate condition-speciﬁc (that is, threatening
faces4shapes) BOLD activation for each individual. These individual
contrast images (that is, weighted sum of the beta images) were then used
in second-level random effects models to determine condition-speciﬁc
amygdala responses. Bilateral amygdala regions of interest were based on
the Automated Anatomical Labeling package of the WFU PickAtlas (v1.04).
All fMRI data are reported using the coordinate system of the Montreal
Neurological Institute. All SPM analyses were thresholded at P=0.05, FWE-
corrected for multiple comparisons across the regions of interest.
Threat-related BOLD parameter estimates were extracted for each
subject from the maximally activated voxels in the right and left amygdala.
The effects of SLC6A3 genotype effects on these BOLD parameter
estimates were analyzed in a regression analysis conducted in SPSS 18
(SPSS). Gender and age were entered as covariates. Multivariate outliers
were identiﬁed by computing Cook’s distance for each observation in
accordance with the above model.
34 Five data points with a Cook’s
distance exceeding the sample-speciﬁc cut-off of 0.045 were removed
from the analyses yielding the ﬁnal sample of 85 from a total sample of 90
subjects. The sample-speciﬁc threshold was calculated as previously
described.
34,35
RESULTS
In neither the PET population nor the fMRI population did the
distribution of observed SLC6A3 genotypes (Table 1) deviate from
Hardy–Weinberg equilibrium. Left amygdala reactivity, that is, the
mean rCBF during the processing of angry faces, as compared
with that during the processing of neutral faces, was positively
associated with the presence of one or two 9-repeats in the
Swedish sample (Table 2, Figure 1), with no indication of an
inﬂuence of diagnostic category (SAD: 9 repeats mean±s.
d.=0.031±0.05, 10 repeats mean±s.d.=0.004±0.02; healthy
volunteer: 9 repeats mean±s.d.=0.024±0.06, 10 repeats mean±
s.d.=−0.003±.03) on this association. This observation is in line
with the results of the US sample of healthy volunteers, in which
amygdala reactivity, that is, regional BOLD parameter estimates
from the comparison of threatening faces and geometric shapes,
was also positively associated with carrying one or two 9-repeats
(n=43) as compared with two 10-repeats (n=42) (Table 2,
Figure 1, Supplementary Figure). Right amygdala reactivity did
not differ between genotypes in either of the two samples
(Table 2).
Table 2. Differences in amygdala reactivity between SLC6A3
dichotomized genotype subgroups in the affective face processing
task
Study population Hemisphere F (df) P
Swedish sample (PET)
Reactivity (angry–neutral faces)
DAT Left 5.07 (1,44) 0.029*
Right 0.005 (1,44) 0.946
DAT×Diagnosis Left 0.01 (1,44) 0.905
Right 0.03 (1,44) 0.855
American sample (fMRI)
Reactivity (threatening faces–geometric shapes)
DAT Left 5.13 (1,81) 0.026*
Right 0.98 (1,81) 0.324
Abbreviations: DAT, dopamine transporter; fMRI, functional magnetic
resonance imaging; PET, positron emission tomography; SAD, social
anxiety disorder; SLC6A3, dopamine transporter gene. For the analysis of
variance of the Swedish sample, diagnostic subgroup (SAD and healthy
volunteer, respectively) was included as a between group factor. For the
analysis of both the Swedish and the US population, sex was included as a
covariate. *Po0.05.
Dopamine transporter and amygdala reactivity
O Bergman et al
3
© 2014 Macmillan Publishers Limited Translational Psychiatry (2014), 1–6DISCUSSION
The possible association between SLC6A3 VNTR and amygdala
reactivity was investigated in two samples, one comprising
Swedish subjects with SAD plus Swedish healthy volunteers
assessed with PET and another one comprising US healthy
volunteers assessed with fMRI. Within both samples, subjects
carrying at least one 9-repeat allele displayed signiﬁcantly higher
left amygdala reactivity than carriers of two 10-repeat alleles.
PET and fMRI have different temporal sensitivity, hence different
tasks, optimized for each modality, were used. Thus, in the PET
study the subjects were shown essentially two long blocks of
either angry or neutral faces, whereas the fMRI paradigm was
based on a rapid shift between angry/fearful faces and
geometrical shapes, respectively. The results thus suggest that
both slow and relatively rapid amygdala reactivity is modulated by
the studied polymorphism.
Importantly, the purpose of this study was to explore the extent
to which the studied polymorphism inﬂuences amygdala reactiv-
ity in humans using two available samples of convenience, one of
which happened to consist partly of subjects suffering from SAD,
an anxiety disorder characterized by a marked and persistent fear
of humiliation or scrutiny in social or performance situations.
27 The
study was hence not prompted by an a priori hypothesis that
patients and healthy volunteers should differ with respect to the
studied association, and it did not have an optimal design for
comparing patients and healthy volunteers as the number of
healthy subjects exposed to the same PET paradigm as the SAD
patients was relatively small. Moreover, a previous study,
comprising partly the same subjects, did not reveal any difference
between SAD patients and controls with respect to amygdala
reactivity assessed using this paradigm.
24 This notwithstanding,
diagnosis was included as a between group factor in the analysis
of covariance by means of which the Swedish data were analyzed,
the outcome of the test, however, suggesting that it did not
inﬂuence the association, which was hence in the same direction
in SAD cases and healthy volunteers.
To the best of our knowledge, this is the ﬁrst study to report on
an association between the VNTR polymorphism in the DAT gene
and amygdala reactivity. The assumption that variations in DA
activity may impact this endophenotype, however, gains support
from several previous association studies. For example, the
val158met polymorphism in the gene encoding the DA-
inactivating enzyme catechol-O-methyl transferase—the
met allele of which tentatively promotes tonic but reduces phasic
dopaminergic transmission
36—has hence been shown to be
associated with amygdala reactivity in several studies. These are,
however, not unanimous with respect to the direction of the effect
or with respect to laterality (for ref see Lonsdorf et al.
37). Of note
are also a few papers reporting associations between polymorph-
isms in the DA D2 receptor gene and the same measure.
38,39
Amygdala reactivity has often been regarded as an endophe-
notype tentatively mediating the effect of genes on anxiety-
related behavior. In this vein, previous studies showing subjects
carrying the short version of the 5-HTTLPR polymorphism in the
Figure 1. Differences (Po0.05) in left amygdala reactivity between SLC6A3 dichotomized genotype subgroups. (a) The amygdala regions of
interest used to extract data in the Swedish sample (PET) are shown overlaid on an anatomical template. (b) Scatter plot showing left
amygdala reactivity in the Swedish sample. (c) The amygdala regions of interest used to extract data in the US sample (fMRI). (d) Scatter plot
showing left amygdala reactivity in the US sample. 9 carriers, carriers of one or two 9-repeats; 10/10, carriers of two 10-repeats; PET, positron
emission tomography; SLC6A3, dopamine transporter gene.
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higher amygdala reactivity than carriers of the long
variant
2,24,40–43 have been regarded as consistent with the
potential association between the short allele of the 5-HTTLPR
and anxiety-related personality traits.
44 Given these previous
observations, the possible inﬂuence of SLC6A3 VNTR on anxiety-
related phenotypes seems to be a topic worth exploring; as yet,
this issue, however, have been only sparsely studied, and data
have been conﬂicting, with no robust support so far for an
association between this polymorphism and anxiety. On the other
hand, there are numerous reports suggesting (albeit not unan-
imously) an association between the 9-repeat allele of the SLC6A3
VNTR with attention deﬁcit hyperactivity disorder (see for example
Brown et al.
45), which is of interest in this context, as subjects with
attention deﬁcit hyperactivity disorder have been reported to
display enhanced activation of the left amygdala when exposed to
threatening faces,
46 and since the increased reactivity is normal-
ized by treatment with central stimulants.
47 Also of note is a
previous report suggesting 9 carriers to display enhanced
detection of novel and behaviorally relevant signals as assessed
by measuring auditory N1 potentials.
48
It has not been obvious how to explain the previously reported
association between 5-HTTLPR and amygdala activity in terms of
serotonergic output. Thus, an allele causing reduced reuptake of
serotonin is associated with an increase in amygdala reactivity,
2
whereas acute administration of a serotonin reuptake inhibitor has
been reported to cause both enhanced
49 and reduced reactivity,
50
and prolonged administration to reduce this measure.
51,52 The
same could be said of the presently reported association of the
SLC6A3 VNTR; thus, although a drug blocking the reuptake of DA
(by reversing the direction of DAT) causes enhanced amygdala
reactivity,
7 we observed subjects carrying a polymorphism
presumably leading to increased DAT expression (for refs, see
Introduction) to display stronger activation of amygdala during
the processing of angry or fearful faces. The reason for these
discrepancies is far from obvious, but it should be underlined that
the output of a certain transmitter may not always be expressed
simply in terms of enhanced or reduced activity. With respect to
dopaminergic activity, many authors have, for example, empha-
sized the importance of separating tonic from phasic activity.
36
Moreover, the possibility that an association between a certain
polymorphism and a certain trait may be due to an inﬂuence
exerted during brain development, rather than in the adult
organism, should not be ignored. Finally, it should be pointed out
that a possible inﬂuence of a polymorphism in the DAT gene on
amygdala reactivity does not necessarily take place in the
amygdala, but can be exerted in another brain region which is
also innervated by dopaminergic nerve terminals and which
exerts an impact on amygdala mediated by non-dopaminergic
neurons.
In conclusion, we demonstrate that variation in the SLC6A3
VNTR polymorphism is of importance for interindividual differ-
ences in amygdala function. This observation is in line with
previous data suggesting (i) the studied polymorphism to be of
functional importance and (ii) amygdala to be under the
inﬂuence of DA.
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